Oluwatosin Smith, MD
Ophthalmology · Dallas, TXNPI 1134150675
Payments from drug & device makers
Across 1,061 payments — averaging $1561.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$830K
- AbbVie$460K
- Bausch & Lomb Americas Inc.$87K
- Alcon$85K
- Aerie Pharmaceuticals, Inc.$62K
- Alcon Research LLC$44K
- plus $88K from 19 others
What the payments were for
- Consulting fees$1,115,87073%
- Speaking & faculty fees$345,31422%
- Grants$10,0001%
- Travel & lodging$43,0313%
- Food & beverage$22,8031%
- Education$70%
- Gifts$900%
- Entertainment$2430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 90 | $829,685 |
| AbbVie(2 entities) | 524 | $459,539 |
| Bausch & Lomb Americas Inc. | 85 | $87,113 |
| Alcon | 126 | $85,350 |
| Aerie Pharmaceuticals, Inc. | 78 | $62,288 |
| Alcon Research LLC | 10 | $44,390 |
| Ocular Therapeutix, Inc. | 2 | $37,333 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 53 | $24,022 |
| NEW World Medical,inc. | 25 | $16,254 |
| Nova Eye, Inc. | 4 | $3,542 |
| Thea Pharma Inc. | 13 | $2,982 |
| Oculus Surgical Inc. | 1 | $1,700 |
| Iridex Corporation | 7 | $739 |
| Sight Sciences, Inc. | 10 | $429 |
| Novartis | 10 | $175 |
| Sun Pharmaceutical Industries Inc. | 5 | $150 |
| Biotissue Holdings Inc. | 5 | $130 |
| Johnson & Johnson Surgical Vision, Inc. | 4 | $112 |
| Rxsight Inc | 1 | $99 |
| Harrow Eye, LLC | 2 | $95 |
| Kala Pharmaceuticals, Inc. | 2 | $38 |
| Dompe US, Inc. | 1 | $34 |
| Oyster Point Pharma, Inc. | 1 | $31 |
| Tarsus Pharmaceuticals, Inc. | 1 | $22 |
| Carl Zeiss Meditec USA, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- iStent Trabecular Micro-Bypass Stent System$298,775
- DURYSTA$175,977
- iStent inject Trabecular Micro-Bypass Stent System$172,500
- iDose$155,179
- Rocklatan$114,829
- VYZULTA$108,432
- Rhopressa$98,229
- iStent$97,500
- iStent inject W$97,500
- LUMIGAN$47,402
- XEN GLAUCOMA TREATMENT SYSTEM$44,674
- Second Generation Travoprost Intracameral Implant (TREX)$36,000
- XEN$30,167
- SIMBRINZA$28,241
- Ahmed Glaucoma Valve$15,790
- Kahook Dual Blade$15,790
- COMBIGAN$13,199
- Hydrus Microstent$10,958
- VUITY$9,899
- Clearpath$7,159
How this compares
$1,656,272 in reported general payments places this provider in the 95th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 374 | $162,321 |
| RhopressaNetarsudil Mesylate | 136 | $69,511 |
| RocklatanNetarsudil Mesylat/Latanoprost | 124 | $65,351 |
| RestasisCyclosporine | 58 | $62,224 |
| CombiganBrimonidine Tartrate/Timolol | 130 | $47,060 |
| VyzultaLatanoprostene Bunod | 110 | $43,093 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 125 | $36,732 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 243 | $31,588 |
| Prednisolone Acetate | 603 | $30,076 |
| MieboPerfluorohexyloctane/Pf | 19 | $19,951 |
| Alphagan PBrimonidine Tartrate | 46 | $19,259 |
| XiidraLifitegrast | 22 | $19,256 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,096 | $18,309 |
| Travoprost | 93 | $15,713 |
| Brinzolamide | 93 | $13,637 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $459,539 | $290,863608 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $62,288 | $134,862260 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Miebo, Xiidra | $87,113 | $82,300151 claims |
| AlconSimbrinza | $85,350 | $36,732125 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm, Prolensa | $24,022 | $17,16573 claims |
| NovartisIlevro | $175 | $4,61612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Dallas
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Jeffrey WhitmanDallas$1.7M
- Davinder GroverDallas$1.3M
- Robert WangDallas$594K
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.